Skip to main content
Abstracts PO59

Cardiac NK/T-Cell Lymphoma: Largest Case Series and MYC Inhibition–Radiation Synergy as a Potential Bridge to Modified SMILE

Guo Qianyu1, 2, 3, 4, Robinson Guy2, 5, Yang William3, 4, Ahmad Ayesha3, 4, 6, Pham Hoang Tran7, Chaludiya Keyur8, Parker Joseph2, 5, Ray Jordan9, Jiang Liuyan10, Tun Han2, 11.

Introduction/Background/Significance: Cardiac involvement by extranodal NK/T-cell lymphoma (ENKTL) is exceedingly rare and almost uniformly fatal, largely because diagnosis is delayed and intensive chemotherapy cannot be delivered promptly. MYC over-expression—common in aggressive or leukemic ENKTL—may represent an actionable radiosensitizing target.

Materials and Methods/Case Presentation/Objective: We retrospectively reviewed three biopsy-proven cases of cardiac ENKTL (largest series to date) and performed a systematic literature review (1960–2025). Two high-MYC leukemic ENKTL patient-derived xenograft (PDX) models were established. Ex-vivo studies compared a small-molecule MYC inhibitor (MYCi-975) ± fractionated irradiation (2 × 2 Gy) against individual SMILE components. Endpoints included viability (CellTiter-Glo), apoptosis (Annexin V/PI), clonogenic survival, and Bliss synergy.

Results/Description/Main Outcome Measures: Median overall survival in our series was 9 days (range 6–36); all patients died before systemic therapy could start. Literature review (n = 19) confirmed 89 % mortality within 30 days. Both PDX lines displayed ≥4-fold higher MYC than non-leukemic ENKTL controls. MYCi-975 monotherapy yielded IC₅₀ ≈ 0.5 μM, inducing >50 % apoptosis at 24 h and >90 % at 72 h. Combining MYCi-975 with 2 × 2 Gy irradiation produced supra-additive cytotoxicity (Bliss excess = 0.23) and >95 % reduction in clonogenic survival versus either treatment alone. RNA-seq showed suppression of pro-proliferative and pro-survival autophagy pathways. No added toxicity was observed in normal PBMCs.

Conclusions: Cardiac ENKTL is rapidly lethal, but MYC inhibition markedly radiosensitizes high-MYC ENKTL models. These findings support a pragmatic bridge strategy—MYCi-975 plus low-dose radiation during critical illness, followed by modified SMILE if the patient stabilizes. Prospective evaluation of MYC-targeted radiosensitization in disseminated ENKTL is urgently warranted.